{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:53:13Z","timestamp":1792666393227,"version":"4.5.0"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Respiratory syncytial virus (RSV) is a leading cause of infant hospitalizations. In August 2023, the US Food and Drug Administration approved a bivalent RSV prefusion F subunit\u2013based vaccine (RSVpreF) for maternal immunization to protect newborns. Sequential surveillance analysis provides information on the safety of a vaccine during its initial uptake.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To report the sequential surveillance findings for 10 prespecified safety outcomes of exposure to RSVpreF during pregnancy over the course of its first vaccination season in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study with a sequential surveillance design used health plan data from 5 research partners. Health insurance data were analyzed across 5 sequential surveillance periods from April 25, 2024, through April 10, 2025. Pregnancies of individuals aged 15 to 54 years that culminated in a live birth or stillbirth and reached 32 gestational weeks were included. Cohorts included pregnancies exposed to RSVpreF (between September 22, 2023, and August 9, 2024); comparator pregnancies receiving influenza, COVID-19, and\/or Tdap (tetanus, diphtheria, and acellular pertussis) vaccines but not the RSVpreF concurrently; and historical comparator pregnancies (vaccinated between September 1, 2018, and January 31, 2023).<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n RSVpreF or comparator vaccines (influenza, COVID-19, and\/or Tdap but not RSVpreF) between 32 through 36 weeks\u2019 gestation.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were preterm birth and pregnancy-associated hypertensive disorders (composite of gestational hypertension; preeclampsia; eclampsia; hemolysis, elevated liver enzymes, and low platelet syndrome; or preexisting hypertension superimposed with preeclampsia or eclampsia). Secondary outcomes included premature rupture of membranes (PROM), preterm labor without preterm delivery, preterm PROM, maternal Guillan-Barr\u00e9 syndrome, and stillbirth. Infant outcomes were large for gestational age, small for gestational age, and low birth weight. Crude incidence proportions (IPs) and adjusted relative risks (ARR) were identified for these outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 13\u202f619 RSVpreF-exposed pregnancies included in the analysis, the mean (SD) maternal age was 33.3 [4.6] years. The most common safety outcomes were pregnancy-associated hypertensive disorders (IP, 17.3%; 95% CI, 16.6%-17.9%) and PROM (IP, 14.1%; 95% CI, 13.5%-14.7%). Risk of preterm birth was not elevated compared with the concurrent comparator (ARR, 0.79; 95% CI, 0.65-0.98) or historical comparator (ARR, 0.87; 95% CI, 0.78-0.96). Beginning with the second surveillance period, statistically significantly elevated risks were detected for pregnancy-associated hypertensive disorders (concurrent comparator: ARR, 1.14 [95% CI, 1.02-1.27]; historical comparator: ARR, 1.29 [95% CI, 1.24-1.34]), PROM (concurrent comparator: ARR, 1.09 [95% CI, 0.97-1.22]; historical comparator: ARR, 1.14 [95% CI, 1.09-1.19]), and preterm PROM (historical comparator: ARR, 1.18; 95% CI, 1.08-1.29). No other increased risks were observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study using a sequential surveillance design, there was no association between RSVpreF vaccination during pregnancy and preterm birth; however, potential increased risks of pregnancy-associated hypertensive disorders, PROM, and preterm PROM could not be ruled out, due to limited confounding control available in the early postlicensure period. Further epidemiological studies are needed to refine risk estimates and account for other confounding factors.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.6190","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:00:23Z","timestamp":1776783623000},"page":"e266190","source":"Crossref","is-referenced-by-count":11,"title":["Sequential Safety Surveillance of RSVpreF Vaccination During Pregnancy Early in the Postapproval Period"],"prefix":"10.1001","volume":"9","author":[{"given":"Ashley I.","family":"Michnick","sequence":"first","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Adimadhyam","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Cosgrove","sequence":"additional","affiliation":[{"name":"Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Petrone","sequence":"additional","affiliation":[{"name":"Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Round","sequence":"additional","affiliation":[{"name":"Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampada","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Koram","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia E.","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rubino","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Lino","sequence":"additional","affiliation":[{"name":"Worldwide Medical and Safety, Pfizer Inc, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba A.","family":"Djibo","sequence":"additional","affiliation":[{"name":"CVS Health, Blue Bell, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Kuntz","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly-Ann M.","family":"Love","sequence":"additional","affiliation":[{"name":"Carelon Research, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl N.","family":"McMahill-Walraven","sequence":"additional","affiliation":[{"name":"CVS Health, Blue Bell, Pennsylvania"},{"name":"Glade Oak Inc, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Palmsten","sequence":"additional","affiliation":[{"name":"Pregnancy and Child Health Research Center, HealthPartners Institute, Bloomington, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Wentz","sequence":"additional","affiliation":[{"name":"Carelon Research, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Andrade","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Platt","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith C.","family":"Maro","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"6","key":"zoi260218r1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"41","key":"zoi260218r2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi260218r3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae544","article-title":"Annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus among US infants aged <12 months.","author":"Houde","journal-title":"J Infect Dis"},{"issue":"9","key":"zoi260218r8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.","volume":"9","author":"Williams","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"zoi260218r9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study.","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"42","key":"zoi260218r10","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"zoi260218r12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi260218r13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/pds.5240","article-title":"A COVID-19-ready public health surveillance system: the Food and Drug Administration\u2019s Sentinel System.","volume":"30","author":"Cocoros","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi260218r14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.320","article-title":"The FDA\u2019s Sentinel Initiative\u2013a comprehensive approach to medical product surveillance.","volume":"99","author":"Ball","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"zoi260218r15","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMp1809643","article-title":"The FDA Sentinel Initiative - an evolving national resource.","volume":"379","author":"Platt","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260218r18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s40264-024-01447-z","article-title":"Use of the Sentinel System to examine medical product use and outcomes during pregnancy.","volume":"47","author":"Lyons","year":"2024","journal-title":"Drug Saf"},{"issue":"5","key":"zoi260218r19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/pds.3407","article-title":"Validation of an algorithm to estimate gestational age in electronic health plan databases.","volume":"22","author":"Li","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi260218r20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/pds.5300","article-title":"Validation of an ICD-10-based algorithm to identify stillbirth in the Sentinel System.","volume":"30","author":"Andrade","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi260218r21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ije\/dyaa252","article-title":"Educational note: addressing special cases of bias that frequently occur in perinatal epidemiology.","volume":"50","author":"Neophytou","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"1","key":"zoi260218r22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/ph18010080","article-title":"Real-time pharmacovigilance: transforming population-based monitoring of post-approval vaccine safety through rapid cycle analysis (RCA)-a review of the published literature.","volume":"18","author":"Gandhi","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"zoi260218r23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40264-023-01324-1","article-title":"Serially combining epidemiological designs does not improve overall signal detection in vaccine safety surveillance.","volume":"46","author":"Arshad","year":"2023","journal-title":"Drug Saf"},{"key":"zoi260218r24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.893484","article-title":"Vaccine safety surveillance using routinely collected healthcare data-an empirical evaluation of epidemiological designs.","volume":"13","author":"Schuemie","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"zoi260218r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003182","article-title":"Atrial fibrillation and atrial flutter in pregnant women-a population-based study.","volume":"5","author":"Lee","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"zoi260218r27","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system, 2009-2010.","volume":"175","author":"Yih","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"1","key":"zoi260218r29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.3547","article-title":"Mini-Sentinel methods: framework for assessment of positive results from signal refinement.","volume":"23","author":"McClure","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi260218r30","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"},{"issue":"25","key":"zoi260218r32","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10","key":"zoi260218r33","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/MLR.0b013e3180616c0a","article-title":"Real-time vaccine safety surveillance for the early detection of adverse events.","volume":"45","author":"Lieu","year":"2007","journal-title":"Med Care"},{"issue":"1","key":"zoi260218r34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/07474946.2011.539924","article-title":"A maximized sequential probability ratio test for drug and vaccine safety surveillance.","volume":"30","author":"Kulldorff","year":"2011","journal-title":"Sequential Anal"},{"key":"zoi260218r35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jclinepi.2019.04.012","article-title":"Leveraging the entire cohort in drug safety monitoring: part 1 methods for sequential surveillance that use regression adjustment or weighting to control confounding in a multisite, rare event, distributed data setting.","volume":"112","author":"Nelson","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"14","key":"zoi260218r36","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination.","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"zoi260218r37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003540","article-title":"Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions.","volume":"6","author":"Dodd","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"22","key":"zoi260218r38","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1002\/sim.9094","article-title":"Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data.","volume":"40","author":"Silva","year":"2021","journal-title":"Stat Med"},{"issue":"3","key":"zoi260218r39","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/biom.12324","article-title":"Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.","volume":"71","author":"Silva","year":"2015","journal-title":"Biometrics"},{"issue":"1","key":"zoi260218r43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12884-021-03938-8","article-title":"Assisted reproductive technology and hypertensive disorders of pregnancy: systematic review and meta-analyses.","volume":"21","author":"Chih","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"issue":"7","key":"zoi260218r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes.","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi260218r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2025.04.067","article-title":"Investigation of maternal outcomes following respiratory syncytial virus vaccination in the third trimester: insights from a real-world United States electronic health records database.","volume":"233","author":"Jin Hsieh","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"zoi260218r48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/AOG.0000000000006121","article-title":"Maternal and neonatal outcomes after respiratory syncytial virus prefusion F protein vaccination during pregnancy: analysis from the 2024-2025 immunization campaign in France.","volume":"147","author":"Gabet","year":"2026","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi260218r49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jama.2025.23452","article-title":"Interim safety of RSVpreF vaccination during pregnancy.","volume":"335","author":"Michnick","year":"2026","journal-title":"JAMA"},{"issue":"2","key":"zoi260218r51","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.60735","article-title":"Respiratory syncytial virus vaccine and nirsevimab uptake among pregnant people and their neonates.","volume":"8","author":"Blauvelt","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260218r52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/HYPERTENSIONAHA.122.19275","article-title":"De novo postpartum hypertension: incidence and risk factors at a safety-net hospital.","volume":"80","author":"Parker","year":"2023","journal-title":"Hypertension"},{"issue":"7","key":"zoi260218r53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1161\/CIRCULATIONAHA.124.073302","article-title":"Hypertension in pregnancy and postpartum: current standards and opportunities to improve care.","volume":"151","author":"Countouris","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"zoi260218r54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40264-022-01261-5","article-title":"Development and validation of ICD-10-CM-based algorithms for date of last menstrual period, pregnancy outcomes, and infant outcomes.","volume":"46","author":"Chomistek","year":"2023","journal-title":"Drug Saf"},{"issue":"4","key":"zoi260218r55","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/EDE.0000000000001343","article-title":"Validation of hypertensive disorders during pregnancy: ICD-10 codes in a high-burden Southeastern United States hospital.","volume":"32","author":"Labgold","year":"2021","journal-title":"Epidemiology"},{"issue":"5","key":"zoi260218r56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035218","article-title":"Validation study: evaluation of the metrological quality of French hospital data for perinatal algorithms.","volume":"10","author":"Goueslard","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"zoi260218r57","first-page":"8","article-title":"Preterm premature rupture of membranes: aggressive tocolysis versus expectant management.","volume":"7","author":"How","year":"1998","journal-title":"J Matern Fetal Med"},{"issue":"3","key":"zoi260218r58","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1067\/mob.2000.106766","article-title":"The preterm prediction study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing.","volume":"183","author":"Mercer","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"zoi260218r59","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators.","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi260218r60","doi-asserted-by":"crossref","DOI":"10.2196\/33099","article-title":"Characterizing anchoring bias in vaccine comparator selection due to health care utilization with COVID-19 and influenza: observational cohort study.","volume":"8","author":"Ostropolets","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"zoi260218r61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jclinepi.2019.04.019","article-title":"Applying sequential surveillance methods that use regression adjustment or weighting to control confounding in a multisite, rare-event, distributed setting: part 2 in-depth example of a reanalysis of the measles-mumps-rubella-varicella combination vaccine and seizure risk.","volume":"113","author":"Cook","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"zoi260218r62","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.3390\/jcm11123452","article-title":"Maternal race and stillbirth: cohort study and systematic review with meta-analysis.","volume":"11","author":"Arechvo","year":"2022","journal-title":"J Clin Med"},{"issue":"13","key":"zoi260218r63","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/1471-0528.18217","article-title":"Measures of structural racism and Black-White disparity in stillbirth rates in New York City, 2009-2018: a population-based cross-sectional study.","volume":"132","author":"Leisher","year":"2025","journal-title":"BJOG"},{"issue":"6","key":"zoi260218r64","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5820","article-title":"Transparency, reproducibility, and replicability of pharmacoepidemiology studies in a distributed network environment.","volume":"33","author":"Rai","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi260218r66","first-page":"1","article-title":"Births: final data for 2022.","volume":"73","author":"Osterman","year":"2024","journal-title":"Natl Vital Stat Rep"},{"key":"zoi260218r4","unstructured":"ABRYSVO. Prescribing information. Pfizer; 2024. Accessed March 2, 2025. https:\/\/www.fda.gov\/media\/168889\/download"},{"key":"zoi260218r5","unstructured":"A phase 2b, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (rsv) vaccine in pregnant women 18 through 49 years of age and their infants. ClinicalTrials.gov identifier: NCT04032093. Updated October 18, 2022. Accessed March 12, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04032093"},{"key":"zoi260218r6","unstructured":"A phase 3, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (rsv) prefusion f subunit vaccine in infants born to women vaccinated during pregnancy. ClinicalTrials.gov identifier: NCT04424316. Updated February 11, 2025. Accessed March 12, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04424316"},{"key":"zoi260218r7","unstructured":"Centers for Disease Control and Prevention. RSV vaccine guidance for pregnant women: respiratory syncytial virus infection (RSV). February 13, 2025. Accessed March 2, 2025. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/pregnant-people.html"},{"key":"zoi260218r11","unstructured":"Pfizer, Inc and Harvard Pilgrim Health Care Institute. A rapid surveillance and cohort post-marketing safety study to evaluate the safety of respiratory syncytial virus vaccine (Abrysvotm) exposure during pregnancy in the United States (C3671027). European Medicines Agency Real World Data Catalogues. October 12, 2024. Accessed March 2, 2025. https:\/\/catalogues.ema.europa.eu\/node\/4016\/administrative-details"},{"key":"zoi260218r16","unstructured":"Sentinel Initiative. Sentinel common data model. Accessed March 2, 2025. https:\/\/www.sentinelinitiative.org\/methods-data-tools\/sentinel-common-data-model"},{"key":"zoi260218r17","unstructured":"Revisions to OMB\u2019s Statistical Policy Directive No. 15: standards for maintaining, collecting, and presenting federal data on race and ethnicity. Office of Information and Regulatory Affairs, Office of Management and Budget, Executive Office of the President; 2024. Accessed November 24, 2025. https:\/\/www.federalregister.gov\/documents\/2024\/03\/29\/2024-06469\/revisions-to-ombs-statistical-policy-directive-no-15-standards-for-maintaining-collecting-and"},{"key":"zoi260218r25","unstructured":"Biologics Effectiveness and Safety Initiative (BEST). Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring. U.S. FDA Center for Biologics Evaluation and Research (CBER); 2021. Accessed March 10, 2025. https:\/\/bestinitiative.org\/wp-content\/uploads\/2022\/01\/C19-Vax-Safety-AESI-Bkgd-Rate-Final-Report-2021.pdf"},{"key":"zoi260218r28","unstructured":"Sentinel Initiative. Mother-infant linkage table. January 31, 2019. Accessed January 9, 2025. https:\/\/www.sentinelinitiative.org\/methods-data-tools\/sentinel-common-data-model\/mother-infant-linkage-table"},{"key":"zoi260218r31","unstructured":"Cole? D, Kulldorff? M, Baker? M, . Infrastructure for evaluation of statistical alerts arising from vaccine safety data mining activities in mini-Sentinel. Harvard Pilgrim Health Care Institute; 2016. Accessed September 19, 2024. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/Methods\/Mini-Sentinel_PRISM_Data-Mining-Infrastructure_Report_0.pdf"},{"key":"zoi260218r40","unstructured":"Sentinel Routine Querying Tool version 13.0.0. Sentinel System. December 13, 2023. Accessed March 17, 2025. https:\/\/dev.sentinelsystem.org\/projects\/SENTINEL\/repos\/sentinel-routine-querying-tool-documentation\/browse?at=refs%2Fheads%2F13.0.0"},{"key":"zoi260218r41","unstructured":"SAS Software Version 9.4. SAS Institute Inc; 2020. Accessed May 1, 2024. https:\/\/www.sas.com"},{"key":"zoi260218r42","unstructured":"Silva? IR. Sequential: exact sequential analysis for Poisson and binomial data. 2024. Accessed May 1, 2024. https:\/\/CRAN.R-project.org\/package=Sequential"},{"key":"zoi260218r44","unstructured":"Moro? PL. Maternal RSV vaccine safety surveillance. Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); June 28, 2024; Atlanta, Georgia. Accessed March 2, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/03-RSV-Mat-Peds-Moro-508.pdf"},{"key":"zoi260218r47","unstructured":"DeSilva? M. Maternal RSV vaccine safety. Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); October 23, 2024; Atlanta, Georgia. Accessed October 24, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/03-RSV-Mat-Peds-DeSilva-508.pdf"},{"key":"zoi260218r50","unstructured":"DeSilva? M. Prenatal RSVpreF vaccine safety 2023\u20132024 respiratory season. The Vaccine Safety Datalink (VSD). Presented at: Meeting of the Advisory Committee on Immunization Practices (ACIP); June 25, 2025; Atlanta, Georgia. Accessed July 9, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/04a-DeSilva-Mat-Peds-RSV-508.pdf"},{"key":"zoi260218r65","unstructured":"Sentinel Data Quality Assurance Practices. Sentinel Initiative. March 23, 2017. Accessed June 2, 2025. https:\/\/www.sentinelinitiative.org\/methods-data-tools\/sentinel-common-data-model\/sentinel-data-quality-assurance-practices"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847996\/michnick_2026_oi_260218_1777316809.66818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:00:26Z","timestamp":1777647626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6190","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}